Welcome to our dedicated page for Xortx Therapeutics news (Ticker: XRTX), a resource for investors and traders seeking the latest updates and insights on Xortx Therapeutics stock.
XORTX Therapeutics Inc. develops therapies for gout and progressive kidney disease, with programs that include XRx-026 for gout, XRx-008 for autosomal dominant polycystic kidney disease, XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections, and XRx-225 for Type 2 diabetic nephropathy. The company also holds the VB4-P5 kidney anti-fibrotic program, a pre-IND asset targeting rare and prevalent forms of kidney disease.
Company announcements cover clinical and preclinical pipeline development, acquired kidney-disease assets, share consolidations, Nasdaq and TSX Venture Exchange listing matters, annual meeting results, board elections, auditor appointments, stock option plan approvals, and other governance actions tied to its public-company status.
XORTX Therapeutics (NASDAQ: XRTX) reminds shareholders to vote for the upcoming Annual and Special Meeting on September 12, 2024. The Board recommends voting FOR ALL proposed items, including:
- Fixing the number of directors at seven
- Electing the board of directors
- Appointing the auditor
- Approving the amended Stock Option Plan
The proxy voting deadline is 10:00 am (Calgary time) on September 10, 2024. Independent proxy advisory firm ISS recommends voting 'FOR' all proposed resolutions. The meeting will be held at XORTX's offices in Calgary. Shareholders can contact Laurel Hill Advisory Group for voting assistance.
XORTX Therapeutics Inc. (NASDAQ: XRTX) highlights recent research indicating genetic factors are linked to over-expression of xanthine oxidase (XO), supporting the company's approach to treating kidney diseases. The research suggests XO modulates progression of chronic kidney disease, diabetic kidney disease, and polycystic kidney disease. CEO Allen Davidoff emphasized the potential of pharmacologic targeting of XO, especially where increased XO activity is associated with kidney diseases.
The company's proprietary formulation, XORLO™, will be tested in a planned clinical trial for patients with autosomal dominant polycystic kidney disease (ADPKD). This trial aims to further understand the role of newly identified genetic factors in individuals with PKD. XORTX believes its expertise in developing XO inhibitors, protected by patents, positions the company to deliver targeted therapeutics to at-risk individuals.
XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU) has announced the filing and mailing of meeting documents for its upcoming Annual and Special Meeting of Shareholders. The management information circular is now available on the company's website, SEDAR+, and the SEC's website. The meeting is scheduled for September 12, 2024, at 10:00 am (Calgary Time) at the company's offices.
Shareholders are encouraged to review the circular and vote their shares by September 10, 2024. The Board of Directors recommends voting FOR ALL proposed items. For assistance with voting, shareholders can contact Laurel Hill Advisory Group. The company also clarified a misreported statement regarding Patrick Treanor's board attendance in 2023.
XORTX Therapeutics Inc. (NASDAQ: XRTX) announced the acceptance of an abstract for presentation at the American Society of Nephrology's Kidney Week 2024. The abstract, titled 'Xanthine oxidase in rats, mice and humans with polycystic kidney disease', focuses on the role of xanthine oxidase (XO) in polycystic kidney disease (PKD). The study, conducted at the University of Colorado and sponsored by XORTX, aimed to understand serum xanthine oxidase activity (XOa) in PKD and its relation to total kidney volume and glomerular filtration rate (GFR) decline.
The research investigated XO activity in PCK1 rats, PKD1RC/RC mice, and 34 patients from the HALT-PKD Clinical study. Results provide insights into how aberrant purine metabolism in PKD tissue may contribute to circulating uric acid levels, kidney expansion rate, and GFR decline. This study builds on previous findings suggesting XO overexpression in PKD kidney tissue. XORTX plans to provide a detailed update on the study results in early November.
XORTX Therapeutics, a late-stage clinical pharmaceutical company focused on treating progressive kidney disease, announces its participation in the BIO International Convention 2024 from June 3-6 at the San Diego Convention Center. CEO Dr. Allen Davidoff will present an overview of the company's progress and future plans on June 4 at 3:30 pm in Theater 1. The event aims to foster outreach to pharmaceutical partners and industry contacts, with over 25 meetings scheduled. One-on-one meetings with Dr. Davidoff can be arranged through the BIO International 2024 meeting platform.
XORTX Therapeutics announced the repricing of warrants issued in October 2021, receiving approval from the TSX Venture Exchange to amend the terms. The repricing affects 101,111 warrants post a 9:1 consolidation, lowering the exercise price from USD $42.93 to USD $5.00. If the company's stock price exceeds USD $6.50 for ten consecutive trading days, warrant holders must exercise their options within 30 days or face expiration.
XORTX Therapeutics Inc. announces the amendment of 1,024,099 outstanding common share purchase warrants by changing the exercise price to USD $5.00 per share. The TSX Venture Exchange approved the amendments related to Private Placements from 2021 to 2022. Additionally, a new Warrant Acceleration Provision was introduced.
Summary not available.
Summary not available.
Summary not available.